Free tool
FAERS Monitor: Tonmya
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219428 or its brand name (Tonmya, Cyclobenzaprine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
8,698
Serious
4,949
57% of reports
Hospitalization
2,222
Death reported
715
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain1,387
- headache1,092
- fatigue1,061
- drug ineffective811
- off label use771
- nausea716
- constipation711
- back pain634
- fall613
- rheumatoid arthritis551
- dyspnoea547
- product dose omission issue519
- diarrhoea518
- hypersensitivity517
- rash514
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 119 |
| 2005 | 123 |
| 2006 | 110 |
| 2007 | 10 |
| 2008 | 24 |
| 2009 | 23 |
| 2010 | 69 |
| 2011 | 103 |
| 2012 | 84 |
| 2013 | 130 |
| 2014 | 97 |
| 2015 | 137 |
| 2016 | 192 |
| 2017 | 206 |
| 2018 | 295 |
| 2019 | 321 |
| 2020 | 480 |
| 2021 | 620 |
| 2022 | 917 |
| 2023 | 942 |
| 2024 | 1,158 |
| 2025 | 1,245 |
| 2026 | 1,292 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,461 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 551 | 11.8 | 10.9 | 5,432 |
| constipationSignal | 711 | 7.9 | 7.4 | 4,313 |
| hypersensitivitySignal | 517 | 6.8 | 6.2 | 2,542 |
| back painSignal | 634 | 6.6 | 6.1 | 3,041 |
| painSignal | 1,387 | 5.5 | 5.2 | 5,203 |
| fallSignal | 613 | 4.5 | 4.1 | 1,665 |
| product dose omission issueSignal | 519 | 4.3 | 3.9 | 1,314 |
| headacheSignal | 1,092 | 4.2 | 4.0 | 2,755 |
| fatigueSignal | 1,061 | 3.3 | 3.1 | 1,760 |
| rashSignal | 514 | 2.9 | 2.6 | 629 |
| dyspnoeaSignal | 547 | 2.3 | 2.2 | 429 |
| nauseaSignal | 716 | 2.2 | 2.0 | 479 |
| off label useSignal | 771 | 2.1 | 2.0 | 481 |
| diarrhoea | 518 | 1.9 | 1.8 | 243 |
| drug ineffective | 811 | 1.5 | 1.4 | 138 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.